Stay updated on CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Sign up to get notified when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.

Latest updates to the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange Detected- Added a prominent funding/status notice and updated to revision v3.2.0. - Removed the previous revision reference v3.1.0.SummaryDifference3%

- Check29 days agoChange DetectedOverall, the page updates to a new revision (v3.1.0) with added contact details and identifiers; the previous revision v3.0.2 was removed.SummaryDifference0.1%

- Check43 days agoChange DetectedPage version updated from v3.0.1 to v3.0.2; no substantive content changes detected; the 'Back to Top' control was removed as a minor UI adjustment.SummaryDifference0.2%

- Check50 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.2%

- Check58 days agoChange DetectedThe web page has been updated to include new facility and location information, as well as additional topics related to colorectal cancer and gastrointestinal diseases. Notably, specific drug names such as cabozantinib, durvalumab, and tremelimumab have been added.SummaryDifference3%

- Check72 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Enter your email address, and we'll notify you when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.